Table 5.
SBRT versus Percutaneous Tumor Ablation (PTA): Multicentric retrospective studies and metanalysis.
Author | Arm | Number of Patients | Tumor Control (%) |
p (After PSM) |
Complications Grade ≥ 3 (%) |
---|---|---|---|---|---|
Kim [39,40] | SBRT | 496 | 3-year LR 21.2 | <0.001 (<0.001) | 1.6 |
PTA | 1568 | 3-year LR 27.9 | 2.6 | ||
Pan [41] | SBRT | 859 | - | 0.003 | - |
PTA | 1873 | - | - | ||
Lee [42] | SBRT | 779 | 2-year LC 84.5 | 0.431 | 0–11.4 |
PTA | 1211 | 2-year LC 79.5 | 0–6.4 |
LR: Local Recurrence; LC; Local Control; PSM: Propensity Score Matching.